Basic Information
| LncRNA/CircRNA Name | LINC00114 |
| Synonyms | NA |
| Region | GRCh38_21:38739021-38747460 |
| Ensemble | ENSG00000223806 |
| Refseq | XR_041645 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | nasopharyngeal cancer |
| ICD-0-3 | C11 |
| Methods | qPCR, Western blot, luciferase reporter assay etc |
| Sample | NPC tissues,cell lines (5-8F and SUNE-1) |
| Expression Pattern | up-regulated |
| Function Description | LINC00114 was upregulated in serums from NPC patients, tissues and cell lines of NPC. LINC00114 knockdown inhibited proliferation, migration, and radioresistance of NPC cells. MiR-203 was a target of LINC00114, and miR-203 inhibition eliminated the effects of LINC00114 knockdown. Besides, the extracellular signal-regulated kinases (ERK)/c-Jun N-terminal kinases (JNK) pathway was inactivated by LINC00114 knockdown but recovered by miR-203 inhibition. |
| Pubmed ID | 32196600 |
| Year | 2020 |
| Title | LINC00114 Promoted Nasopharyngeal Carcinoma Progression and Radioresistance in Vitro and in Vivo Through Regulating ERK/JNK Signaling Pathway via Targeting miR-203 |
External Links
| Links for LINC00114 | GenBank HGNC NONCODE |
| Links for nasopharyngeal cancer | OMIM COSMIC |